DNLI
Denali Therapeutics Inc.NASDAQHealthcare$20.65+4.93%ClosedMarket Cap: $3.27B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.35
P/S
0.00
EV/EBITDA
-5.47
DCF Value
$0.92
FCF Yield
-13.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-50.1%
ROA
-44.8%
ROIC
-52.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-137.4M | $-128.5M | $-0.73 | — |
| FY 2025 | $0.00 | -Infinity% | $-555.3M | $-512.5M | $-2.97 | — |
| Q3 2025 | $0.00 | NaN% | $-137.4M | $-126.9M | $-0.74 | — |
| Q2 2025 | $0.00 | NaN% | $-135.0M | $-124.1M | $-0.72 | — |
| Q1 2025 | $0.00 | NaN% | $-145.6M | $-133.0M | $-0.78 | — |
| Q4 2024 | $0.00 | NaN% | $-129.8M | $-114.8M | $-0.67 | — |
| FY 2024 | $0.00 | NaN% | $-487.3M | $-422.8M | $-2.57 | — |
| Q3 2024 | $0.00 | NaN% | $-123.2M | $-107.2M | $-0.63 | — |
| Q2 2024 | $0.00 | NaN% | $-116.6M | $-99.0M | $-0.59 | — |
| Q1 2024 | $0.00 | NaN% | $-117.7M | $-101.8M | $-0.68 | — |
| Q4 2023 | $0.00 | NaN% | $-132.6M | $-119.5M | $-0.86 | — |
| FY 2023 | $330.5M | 100.0% | $-196.7M | $-145.2M | $-1.06 | — |